1 / 17

Translational Research Program

Translational Research Program. An Overview: 2000-2005. Mission. The Translational Research Program was designed to provide the laboratory component for achieving the overall INCTR mission of improving clinical outcome of cancer patients from developing countries.

Sophia
Télécharger la présentation

Translational Research Program

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Translational Research Program An Overview: 2000-2005 Annual Meeting 2005

  2. Mission • The Translational Research Program was designed to provide the laboratorycomponent for achieving the overall INCTR mission of improving clinical outcome of cancer patients from developing countries. • Laboratory for generation of molecular correlates from clinical studies. • Conduct molecular epidemiological and educational programs.

  3. Objectives • Major elements of the program driven by • Clinical studies conducted by INCTR (ALL in India) • Epidemiological studies of interest to INCTR • Differences in distribution of molecular subtypes of ALLs • Gene-environment interactions modulating oncogenic translocations • Epigenetic changes in bladder ca. modulated by infection • Enable capacity building • Training in molecular biology platforms that can provide clinically relevant tools • Pilot research studies for future fundable programs (ALL in India)

  4. Specific ObjectivesBidirectional Interactions • Catalyze the translation of unique clinical observations from the patient setting in developing countries to a laboratory environment. • Is outcome of childhood ALL a function of the subtype distribution? • Rapidly move key and novel laboratory observations made in the West, to the patient setting in developing countries. • Are novel tumor types identified by molecular profiling clinically relevant in low resource settings?

  5. Resources • Human • Scientists & technicians from KFNCCC&R • Trainees from developing countries • Space • KFNCCC&R, Riyadh, Saudi Arabia • Facilities • PCR, real time PCR, sequencer, tissue arrayer, microarrays, more. • Major Collaborators • 3 Indian Institutions (TMH, AIIMS, WIA) • NCI, Cairo, Egypt • Univ of Istanbul, Turkey

  6. TUMOR SAMPLES Strategy

  7. ALL Program 5 Projects: • Molecular subclassification • Gene expression profiling • Epigenetics • Pharmacogenetics • Proteomics of Apoptosis - target for treatment

  8. ALL Program1- Molecular subclassification • Real-time RT-PCR for most common chromosomal translocations • Trained laboratory staff of INCTR centers in India • SOP for sample collection, storage, usage and analyses • Distribution of molecular subgroups TEL-AML1 are less frequent, BCR-ABLs are more frequent in India but not in Saudi Arabia • Clin Cancer Res, 2002 Leukemia, 2003 Am J Hematol, 2004 J Mol Diagnostics, 2005 • Clinical correlates - recent INCTR protocol

  9. ALL Program2- Gene Expression Profiling • Real-time RT-PCR validation of data from the West • VEGF and its receptors are expressed in ALL • TEL/ETV6 expression can identify 12p del • Hox11L2 expression in T-ALL • Novel molecular subgroup identified in the West (Yeoh et al) is also found in India • Leuk Res, 2004 Int J Biol Markers, 2004 Cancer Lett (in press) • Affymetrix microarrays

  10. ALL Program3- Epigenetics • MSP and COBRA assays for multiple genes and sequence analyses • Concurrent methylation pattern of ALL • E-cad is frequently methylated • B > T MLL > E2A-PBX1 • Differences with adult ALL • Less epigenetic lesions in cell cycle genes • Comparison with AML • Methylator phenotype: DAP-Kinase, p15, ER, SOCS1 • Peak of methylation in young adults • Leukemia 2003 Cancer Epidemiol Biomarkers Prev 2003 Am J Hematol 2004, 2005

  11. ALL Program4- Pharmacogenetics • PCR-RFLP assays for multiple genes involved in metabolization of drugs and xenobiotics. • Population-based: SNPs influencing cancer risk • Middle-Eastern Arab population • The Pharmacogenomic J, 2004 • Patient-based: SNPs determining risk of toxicity and efficacy of treatment • Over 200 Indian patients • 100 pts in MCP943 • Clinical correlates: level of toxicity?

  12. ALL Program5- Proteomics of Apoptosis • Standardized Western blot assay for proteins involved in the intrinsic and extrinsic pathways of apoptosis using cell lines. • Validated its application in clinical samples. • Proof of principle: Apoptosis as a target for therapy. • Haematologica 2003 Leuk & Lymphoma 2004 Genes, Chromosomes Cancer 2004

  13. Additional ActivitiesManagement of ALL • Real time PCR assay for detection and quantification of fungal infections – can predict IFI? Preemptive therapy? • J Med Microbiol 2005 • Proof of principle of a novel marker of MRD and CNS involvement in ALL and AML (real time quantitative PCR for TdT) • Haematologica (2nd revision) • Real time PCR assay for EBV load (BMT).

  14. Other Activities • Epigenetics of Bilharzial bladder cancer • SA > NSA • Modern Pathol 2004 • Geographic variation of oncogenic transl. in healthy individuals (Middle Eastern Arabs) • JH-BCL2 - 37% (> in older individuals) • BCR-ABL – 27% • TEL-AML1 – 4% • More than 1 translocation increased with age • Modulation by SNPs in DNA repair and synthesis genes (37 SNPs in 11 genes). • Manuscript in preparation

  15. Future Directions1-Improvements • Provide the missing clinical links to prove the reliability and the usefulness of the assays and biomarkers developed. • Recent INCTR Protocol for ALL (India) • Uniform data collection and availability. • Establish a quality control system.

  16. Future Directions2-Pathway • Comprehensively pursue the ALL translational program in India. • The pilot ALL project has already provided: • basic ground work to define feasibility. • technological training and capacity. • identified the team process required. • Now the Indo Leukemia Study Group should engage in writing a proposal to attract funding.

  17. Future Directions3-Suggested Steps 1) Form a strategy group to prioritize the clinical and translational questions. Coordination and quality control. 2) Use data from the pilot project to write a grant application. 3) Identify partners (investigators from USA/ Europe) who can provide additional technological expertise and extend comparative studies. 4) Identify funding sources that will consider the proposal.

More Related